MIRM: Nilai perusahaan marang bathi resik Mirum Pharma

Mirum Pharmaceuticals (MIRM) management has solidified its dominance in the treatment of pediatric cholestatic pathologies through patents. The business's P/E ratio visualizes this success, with the current level standing at -6.90. Growth is accelerating through the implementation of AI platforms for rare disease analysis, while the expansion strategy into new indications aims for the complete monopolization of the liver therapy niche.

MIRM - Pangali P/E Mirum ing rentang 04.07.2022 - 15.11.2026

Rincian metrik komprehensif lan analitis Mirum Pharmaceuticals, Inc. (MIRM)

- rega lan prakiraan konsensus rega:

Rega saham Mirum Pharma|MIRM - Target konsensus

- informasi kapitalisasi pasar:

Nilai pasar Mirum Pharma|MIRM - Nilai Total Perusahaan

- indikator nilai aset resik miturut neraca:

Aset Bersih saben Siji Saham Mirum Pharmaceuticals|MIRM - Kapitalisasi Buku|Kapitalisasi Pasar marang Nilai Buku mirumpharma.com|MIRM - Gunggung Aset Perusahaan

- data liabilitas lan likuiditas perusahaan:

Utang marang Ekuitas Mirum Pharmaceuticals|MIRM - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal mirumpharma.com|MIRM - Utang perusahaan|Rasio utang marang aset resik Mirum Pharma|MIRM - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Mirum Pharmaceuticals|Koefisien jangkoan perantara mirumpharma.com

- statistik bathi lan rasio pasar:

MIRM - Bathi resik perusahaan|Penghasilan resik sing dikarepake Mirum Pharmaceuticals|MIRM - Koefisien rega marang bathi|Pangali Forward P/E Mirum Pharmaceuticals Inc|MIRM - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Mirum Pharmaceuticals Inc|MIRM - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajroning taun lumaku Mirum Pharmaceuticals|MIRM - Bathi saben saham sajrone rolas wulan pungkasan|Dinamika bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan mirumpharma.com|MIRM - Wutah bathi ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Mirum Pharmaceuticals

- statistik dodolan lan pendapatan perusahaan:

MIRM - Pendapatan lan volume dodolan|Prakiraan volume dodolan Mirum Pharmaceuticals, Inc.|MIRM - Rasio rega marang pendapatan|Rega forward marang dodolan Mirum Pharma

Analisis komprehensif perusahaan:Mirum Pharmaceuticals, Inc. - MIRM

Market expectations for Mirum Pharmaceuticals (MIRM) depend on the ratio of market capitalization to net income, which allows for an assessment of the cost per unit of earnings. By analyzing the company's fundamental P/E, an investor can see how scaling sales of orphan drugs offsets fixed R&D costs, transforming the biotech asset into a commercially efficient business with growing operating margins.

Analisis perusahaan pesaing

Pangali P/E Arrowhead Pharmaceuticals Inc|Koefisien rega marang bathi DVAX (Dynavax Technologies)|ABUS (Tekmira Pharmaceuticals) - Nilai perusahaan marang bathi resik|Pangali P/E IVA (inventivapharma.com)|Gyre Therapeutics, Inc. - Rasio rega marang bathi|Assembly Bio - Pangali P/E|Periode bali modal bisnis Galectin Therapeutics, Inc. GALT|GNFT (Genfit SA) - Koefisien rega marang bathi|DRRX (DURECT Corp) - Rasio rega marang bathi|ALGS (Aligos Therapeutics Inc.) - Pangali P/E|Kapitalisasi marang bathi biovieinc.com BIVI|Rasio rega marang bathi Galmed Pharmaceuticals Ltd (GLMD)|NDRA (ENDRA Life Sciences Inc.) - Nilai perusahaan marang bathi resik|Pangali P/E HEPA (Hepion Pharmaceuticals)